Prostatic Artery Embolization (PAE) for Symptomatic Benign Prostatic Hyperplasia (BPH): Part 1, Pathological Background and Clinical Implications

详细信息    查看全文

• 作者：Fei Sun ; Verónica Crisóstomo…
• 关键词：Benign prostatic hyperplasia ; Prostatic artery embolization ; Lower urinary tract symptoms ; Pathology
• 刊名：CardioVascular and Interventional Radiology
• 出版年：2016
• 出版时间：January 2016
• 年：2016
• 卷：39
• 期：1
• 页码：1-7
• 全文大小：374 KB
• 参考文献：1.Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol. 1984;132(3):474–9.PubMed
  2.Pisco J, Campos Pinheiro L, Bilhim T, Duarte M, RioTinto H, Fernandes L, Vaz Santos V, Oliveira AG. Prostatic arterial embolization for benign prostatic hyperplasia: short- and intermediate-term results. Radiology. 2013;266(2):668–77.PubMed CrossRef
  3.Carnevale FC, da Motta-Leal-Filho JM, Antunes AA, Baroni RH, Marcelino AS, Cerri LM, Yoshinaga EM, Cerri GG, Srougi M. Quality of life and clinical symptom improvement support prostatic artery embolization for patients with acute urinary retention caused by benign prostatic hyperplasia. J Vasc Interv Radiol. 2013;24(4):535–42.PubMed CrossRef
  4.Bagla S, Martin CP, van Breda A, Sheridan MJ, Sterling KM, Papadouris D, Rholl KS, Smirniotopoulos JB, van Breda A. Early results from a United States trial of prostatic artery embolization in the treatment of benign prostatic hyperplasia. J Vasc Interv Radiol. 2014;25(1):47–52.PubMed CrossRef
  5.Carnevale FC, Moreira AM, Antunes AA. The “PErFecTED technique”: proximal embolization first, then embolize distal for benign prostatic hyperplasia. Cardiovasc Intervent Radiol. 2014;37(6):1602–5.PubMed CrossRef
  6.Golzarian J, Antunes AA, Bilhim T, Carnevale FC, Konety B, McVary KT, Parsons JK, Pisco JM, Siegel DN, Spies J, Wasserman N, Gowda N, Ahrar K. Prostatic artery embolization to treat lower urinary tract symptoms related to benign prostatic hyperplasia and bleeding in patients with prostate cancer: proceedings from a multidisciplinary research consensus panel. J Vasc Interv Radiol. 2014;25(5):665–74.PubMed CrossRef
  7.Roehrborn CG. Benign prostatic hyperplasia: etiology, pathophysiology, epidemiology, and natural history. In: Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA, editors. Campbell-Walsh Urology. 10th ed. Philadelphia: Saunders; 2012. p. 2570–610.CrossRef
  8.Madersbacher S, Klingler HC, Schatzl G, Stulnig T, Schmidbauer CP, Marberger M. Age related urodynamic changes in patients with benign prostatic hyperplasia. J Urol. 1996;156(5):1662–7.PubMed CrossRef
  9.Dmochowski RR. Bladder outlet obstruction: etiology and evaluation. Rev Urol. 2005;7(Suppl 6):S3–13.PubMed PubMedCentral
  10.Peters CA, Walsh PC. The effect of nafarelin acetate, a luteinizing-hormone-releasing hormone agonist, on benign prostatic hyperplasia. N Engl J Med. 1987;317(10):599–604.PubMed CrossRef
  11.Saartok T, Dahlberg E, Gustafsson JA. Relative binding affinity of anabolic-androgenic steroids: comparison of the binding to the androgen receptors in skeletal muscle and in prostate, as well as to sex hormone-binding globulin. Endocrinology. 1984;114(6):2100–6.PubMed CrossRef
  12.Andriole G, Bruchovsky N, Chung LW, Matsumoto AM, Rittmaster R, Roehrborn C, Russell D, Tindall D. Dihydrotestosterone and the prostate: the scientific rationale for 5alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia. J Urol. 2004;172(4 Pt 1):1399–403.PubMed CrossRef
  13.Partin AW, Oesterling JE, Epstein JI, Horton R, Walsh PC. Influence of age and endocrine factors on the volume of benign prostatic hyperplasia. J Urol. 1991;145(2):405–9.PubMed
  14.Sonke GS, Mochtar CA, Kiemeney LALM. Etiology of benign prostatic hyperplasia. In: Kirby RS, McConnell JD, Fitzpatrick JM, Roehrborn CG, Boyle P, editors. Textbook of benign prostatic hyperplasia. 2nd ed. Oxfordshire: Taylor & Francis; 2005. p. 2570–610.
  15.Niu Y, Xu Y, Zhang J, Bai J, Yang H, Ma T. Proliferation and differentiation of prostatic stromal cells. BJU Int. 2001;87(4):386–93.PubMed CrossRef
  16.Kim IY, Zelner DJ, Sensibar JA, Ahn HJ, Park L, Kim JH, Lee C. Modulation of sensitivity to transforming growth factor-beta 1 (TGF-beta 1) and the level of type II TGF-beta receptor in LNCaP cells by dihydrotestosterone. Exp Cell Res. 1996;222(1):103–10.PubMed CrossRef
  17.Levine AC, Liu XH, Greenberg PD, Eliashvili M, Schiff JD, Aaronson SA, Holland JF, Kirschenbaum A. Androgens induce the expression of vascular endothelial growth factor in human fetal prostatic fibroblasts. Endocrinology. 1998;139(11):4672–8.PubMed
  18.Hammarsten J, Högstedt B, Holthuis N, Mellström D. Components of the metabolic syndrome-risk factors for the development of benign prostatic hyperplasia. Prostate Cancer Prostatic Dis. 1998;1(3):157–62.PubMed CrossRef
  19.Hammarsten J, Högstedt B. Clinical, anthropometric, metabolic and insulin profile of men with fast annual growth rates of benign prostatic hyperplasia. Blood Press. 1999;8(1):29–36.PubMed CrossRef
  20.Ziada A, Rosenblum M, Crawford ED. Benign prostatic hyperplasia: an overview. Urology. 1999;53(3 Suppl 3a):1–6.PubMed CrossRef
  21.Ghafar MA, Puchner PJ, Anastasiadis AG, Cabelin MA, Buttyan R. Does the prostatic vascular system contribute to the development of benign prostatic hyperplasia? Curr Urol Rep. 2002;3(4):292–6.PubMed CrossRef
  22.Berger AP, Deibl M, Leonhartsberger N, Bektic J, Horninger W, Fritsche G, Steiner H, Pelzer AE, Bartsch G, Frauscher F. Vascular damage as a risk factor for benign prostatic hyperplasia and erectile dysfunction. BJU Int. 2005;96(7):1073–8.PubMed CrossRef
  23.Berger AP, Bartsch G, Deibl M, Alber H, Pachinger O, Fritsche G, Rantner B, Fraedrich G, Pallwein L, Aigner F, Horninger W, Frauscher F. Atherosclerosis as a risk factor for benign prostatic hyperplasia. BJU Int. 2006;98(5):1038–42.PubMed CrossRef
  24.Deipolyi AR, Al-Ansari S, Khademhosseini A, Oklu R. Occlusion of the internal iliac artery is associated with smaller prostate and decreased urinary tract symptoms. J Vasc Interv Radiol. 2015;26(9):1305–10.PubMed CrossRef
  25.Claus S, Wrenger M, Senge T, Schulze H. Immunohistochemical determination of age related proliferation rates in normal and benign hyperplastic human prostates. Urol Res. 1993;21(5):305–8.PubMed CrossRef
  26.McNeal JE. Regional morphology and pathology of the prostate. Am J Clin Pathol. 1968;49(3):347–57.PubMed
  27.Myers RP. Structure of the adult prostate from a clinician’s standpoint. Clin Anat. 2000;13(3):214–5.PubMed CrossRef
  28.McNeal JE. The zonal anatomy of the prostate. Prostate. 1981;2(1):35–49.PubMed CrossRef
  29.McNeal JE. Origin and evolution of benign prostatic enlargement. Invest Urol. 1978;15(4):340–5.PubMed
  30.McNeal J. Pathology of benign prostatic hyperplasia. Insight into etiology. Urol Clin North Am. 1990;17(3):477–86.PubMed
  31.Bartsch G, Müller HR, Oberholzer M, Rohr HP. Light microscopic stereological analysis of the normal human prostate and of benign prostatic hyperplasia. J Urol. 1979;122(4):487–91.PubMed
  32.Aoki Y, Arai Y, Maeda H, Okubo K, Shinohara K. Racial differences in cellular composition of benign prostatic hyperplasia. Prostate. 2001;49(4):243–50.PubMed CrossRef
  33.Robert M, Costa P, Bressolle F, Mottet N, Navratil H. Percentage area density of epithelial and mesenchymal components in benign prostatic hyperplasia: comparison of results between single biopsy, multiple biopsies and multiple tissue specimens. Br J Urol. 1995;75(3):317–24.PubMed CrossRef
  34.Lepor H, Shapiro E, Wang B, Liang YC. Comparison of the cellular composition of benign prostatic hyperplasia in Chinese and Caucasian-American men. Urology. 1996;47(1):38–42.PubMed CrossRef
  35.Shapiro E, Becich MJ, Hartanto V, Lepor H. The relative proportion of stromal and epithelial hyperplasia is related to the development of symptomatic benign prostate hyperplasia. J Urol. 1992;147(5):1293–7.PubMed
  36.Shapiro E, Hartanto V, Lepor H. The response to alpha blockade in benign prostatic hyperplasia is related to the percent area density of prostate smooth muscle. Prostate. 1992;21(4):297–307.PubMed CrossRef
  37.Bostwick DG. The pathology of benign prostatic hyperplasia. In: Kirby RS, McConnell JD, Fitzpatrick JM, Roehrborn CG, Boyle P, editors. Textbook of benign prostatic hyperplasia. 2nd ed. Oxfordshire: Taylor & Francis; 2005. p. 97–111.
  38.Mebust WK, Holtgrewe HL, Cockett AT, Peters PC. Transurethral prostatectomy: immediate and postoperative complications. A cooperative study of 13 participating institutions evaluating 3885 patients. J Urol. 1989;141(2):243–7.PubMed
  39.Lynch TH, Waymont B, Dunn JA, Hughes MA, Wallace DM. Rapid diagnostic service for patients with haematuria. Br J Urol. 1994;73(2):147–51.PubMed CrossRef
  40.Hasan ST, German K, Derry CD. Same day diagnostic service for new cases of haematuria–a district general hospital experience. Br J Urol. 1994;73(2):152–4.PubMed CrossRef
  41.Foley SJ, Soloman LZ, Wedderburn AW, Kashif KM, Summerton D, Basketter V, Holmes SA. A prospective study of the natural history of hematuria associated with benign prostatic hyperplasia and the effect of finasteride. J Urol. 2000;163(2):496–8.PubMed CrossRef
  42.Foley SJ, Bailey DM. Microvessel density in prostatic hyperplasia. BJU Int. 2000;85(1):70–3.PubMed CrossRef
  43.Bigler SA, Deering RE, Brawer MK. Comparison of microscopic vascularity in benign and malignant prostate tissue. Hum Pathol. 1993;24(2):220–6.PubMed CrossRef
  44.Deering RE, Bigler SA, Brown M, Brawer MK. Microvascularity in benign prostatic hyperplasia. Prostate. 1995;26(3):111–5.PubMed CrossRef
  45.Jacobsen SJ, Girman CJ, Guess HA, Rhodes T, Oesterling JE, Lieber MM. Natural history of prostatism: longitudinal changes in voiding symptoms in community dwelling men. J Urol. 1996;155(2):595–600.PubMed CrossRef
  46.Roberts RO, Jacobsen SJ, Jacobson DJ, Rhodes T, Girman CJ, Lieber MM. Longitudinal changes in peak urinary flow rates in a community based cohort. J Urol. 2000;163(1):107–13.PubMed CrossRef
  47.Rhodes T, Girman CJ, Jacobsen SJ, Roberts RO, Guess HA, Lieber MM. Longitudinal prostate growth rates during 5 years in randomly selected community men 40 to 79 years old. J Urol. 1999;161(4):1174–9.PubMed CrossRef
  48.EzzelDin K, Kiemeney LA, de Wildt MJ, Debruyne FM, de la Rosette JJ. Correlation between uroflowmetry, prostate volume, postvoid residue, and lower urinary tract symptoms as measured by the International Prostate Symptom Score. Urology. 1996;48(3):393–7.CrossRef
  49.Barry MJ, Cockett AT, Holtgrewe HL, McConnell JD, Sihelnik SA, Winfield HN. Relationship of symptoms of prostatism to commonly used physiological and anatomical measures of the severity of benign prostatic hyperplasia. J Urol. 1993;150(2 Pt 1):351–8.PubMed
  50.Jacobsen SJ, Jacobson DJ, Girman CJ, Roberts RO, Rhodes T, Guess HA, Lieber MM. Natural history of prostatism: risk factors for acute urinary retention. J Urol. 1997;158(2):481–7.PubMed CrossRef
  51.Jacobsen SJ, Jacobson DJ, Girman CJ, Roberts RO, Rhodes T, Guess HA, Lieber MM. Treatment for benign prostatic hyperplasia among community dwelling men: the Olmsted County study of urinary symptoms and health status. J Urol. 1999;162(4):1301–6.PubMed CrossRef
  52.McVary KT. Prostatic arterial embolization for LUTS/BPH-an opportunity for collaborative research or next prostatic gizmo candidate? J Urol. 2014;191(3):577–8.PubMed CrossRef
  53.Lepor H. Editorial comment to: Three-year safety and efficacy data on the use of finasteride in the treatment of benign prostatic hyperplasia. Stoner E and the Members of the Finasteride Study Group. Urology. 1994; 43(3): 292–293.
  54.Charlton RG, Morley AR, Chambers P, Gillespie JI. Focal changes in nerve, muscle and connective tissue in normal and unstable human bladder. BJU Int. 1999;84(9):953–60.PubMed CrossRef
  55.O’Reilly BA, Kosaka AH, Chang TK, Ford AP, Popert R, McMahon SB. A quantitative analysis of purinoceptor expression in the bladders of patients with symptomatic outlet obstruction. BJU Int. 2001;87(7):617–22.PubMed CrossRef
  56.Levin RM, Haugaard N, O’Connor L, Buttyan R, Das A, Dixon JS, Gosling JA. Obstructive response of human bladder to BPH vs. rabbit bladder response to partial outlet obstruction: a direct comparison. Neurourol Urodyn. 2000;19(5):609–29.PubMed CrossRef
  57.Jaffe WI, Te AE. Overactive bladder in the male patient: epidemiology, etiology, evaluation, and treatment. Curr Urol Rep. 2005;6(6):410–8.PubMed CrossRef
  58.Abrams PH, Farrar DJ, Turner-Warwick RT, Whiteside CG, Feneley RC. The results of prostatectomy: a symptomatic and urodynamic analysis of 152 patients. J Urol. 1979;121(5):640–2.PubMed
  59.Rollema HJ, Van Mastrigt R. Improved indication and followup in transurethral resection of the prostate using the computer program CLIM: a prospective study. J Urol. 1992;148(1):111–5.PubMed
  60.Lemack GD, McConnell JD. Bladder responses to obstruction. In: Kirby RS, McConnell JD, Fitzpatrick JM, Roehrborn CG, Boyle P, editors. Textbook of benign prostatic hyperplasia. 2nd ed. Oxfordshire: Taylor & Francis; 2005. p. 113–8.
  61.George NJ, Feneley RC, Roberts JB. Identification of the poor risk patient with “prostatism” and detrusor failure. Br J Urol. 1986;58(3):290–5.PubMed CrossRef
  62.Kaplan SA, Bowers DL, Te AE, Olsson CA. Differential diagnosis of prostatism: A 12-year retrospective analysis of symptoms, urodynamics and satisfaction with therapy. J Urol. 1996;155(4):1305–8.PubMed CrossRef
  
• 作者单位：Fei Sun (1)
  Verónica Crisóstomo (1)
  Claudia Báez-Díaz (1)
  Francisco M. Sánchez (1)
  
  1. Jesús Usón Minimally Invasive Surgery Centre, Carretera N-521, km. 41.8, 10071, Cáceres, Spain
  
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Imaging and Radiology
  Nuclear Medicine
  Ultrasound
  Cardiology
  
• 出版者：Springer New York
• ISSN：1432-086X

文摘

Pathological features of benign prostatic hyperplasia (BPH) dictate various responses to prostatic artery embolization (PAE). Typically, BPH originates in the transition zone and periurethral region, where should be considered the primary target area in PAE procedures. Given that histological heterogeneity of components in hyperplasia nodules, epithelial or stromal, identifying the more responsive nodules to PAE will have clinical implications. Since some lower urinary tract symptoms (LUTS) in patients with BPH are usually related to bladder outlet obstruction-induced changes in bladder function rather than to outflow obstruction directly, proper selection of candidate patients prior to PAE is of great clinical importance. BPH is a typical chronic progressive condition, suggesting PAE could aim not only to relieve LUTS but also to delay or prevent the clinical progression. Awareness of the pathological background of BPH is essential for interventional radiologists to improve clinical outcomes and develop new treatment strategies in clinical practice of PAE. Keywords Benign prostatic hyperplasia Prostatic artery embolization Lower urinary tract symptoms Pathology